Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2017-11-17 Director's Dealing
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Powiadomienie o transakcjach osoby pełniącej obowiązki zarządcze. - Content (PL)
Director's Dealing Classification · 98% confidence The document text is very short (249 characters) and states that the Management Board received a notification from the CEO regarding transactions in the company's shares ('transakcjach na akcjach Spółki') and that the content of the notification is attached to the current report. This structure—a brief announcement referencing an attached document detailing insider transactions—strongly suggests a Director's Dealing report notification. The specific code for Director's Dealing is DIRS.
2017-11-17 Polish
Zawiadomienie o transakcjach na akcjach GLG Pharma S.A.
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). It details a transaction involving a person discharging managerial responsibilities ("Piotr Sobis," CEO) concerning the acquisition ('nabycie') of company shares ('Akcje'). This structure and content explicitly describe insider trading or director's dealing activities as mandated by market abuse regulations (MAR). This directly corresponds to the definition for Director's Dealing (DIRS).
2017-11-16 Polish
Powiadomienie o transakcjach osoby pełniącej obowiązki zarządcze. - Content (PL)
Director's Dealing Classification · 98% confidence The document text is very short (249 characters) and states that the Management Board ('Zarząd') received a notification from the CEO ('Prezesa Zarządu') regarding transactions in the company's shares ('transakcjach na akcjach Spółki'). It explicitly mentions that the content of the notification is attached to the current report ('Treść powiadomienia Spółka przekazuje w załączeniu do niniejszego raportu'). This structure—a brief announcement stating that a report about insider transactions is attached—strongly suggests a Director's Dealing notification (DIRS) being filed, but because the text itself is only the announcement of the filing, and not the detailed transaction report, it fits the 'MENU VS MEAL' rule. However, DIRS is a specific category for director transactions. Given the content explicitly details a notification about transactions by the CEO, the primary subject is Director's Dealing (DIRS). If DIRS were not available, RPA might apply, but DIRS is more specific to the content described (insider transaction notification). Since the text describes the receipt and forwarding of a director's transaction notification, DIRS is the most appropriate specific code, even if it's a short announcement.
2017-11-16 Polish
Pozostałe informacje do raportu kwartalnego Celon Pharma S.A.
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly report ('raport kwartalny') for Celon Pharma S.A. for the third quarter of 2017. It contains detailed financial data, management discussion, shareholding structure, and board information. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2017
2017-11-15 Polish
Podpisanie umowy z NCBR o dofinansowanie projektu dotyczącego rozwoju przedklinicznego i klinicznego inhibitora ścieżki ubikwityna-proteasom - Content (PL)
Capital/Financing Update Classification · 98% confidence The document text is very short (948 characters) and references a previous current report (raport bieżący nr 18/2017). It announces that the company has received knowledge about the signing of a co-financing agreement (umowy o dofinansowanie) from the National Centre for Research and Development (NCBR) for a specific project, detailing the total cost and the granted funding amount (25.6 million PLN). This is a specific update regarding financing/funding for a project, which aligns best with the Capital/Financing Update category (CAP). It is not a full report, an earnings release, or a management discussion, but a specific announcement about securing funds.
2017-11-10 Polish
Rejestracja leku Salmex na rynku w Portugalii - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a short announcement (898 characters) from the Management Board ('Zarząd') of Celon Pharma S.A. It reports on the registration of a drug (Salmex) in Portugal via a business partner. This type of specific, material, non-financial operational update, which is not a standard SEC filing (like 10-K or ER), is best classified as a general Regulatory Filing (RNS) or potentially a Legal/Operational update. Since it details a specific business event (drug registration/market expansion) that is material but doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Director Dealing (DIRS), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements not covered elsewhere. Given the context of reporting material information, RNS is the best fit.
2017-11-03 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.